



For Immediate Release.....

**NBMI Research Collaboration to Present Findings at
Conference in Prague, Czech Republic**

Edmond, OK (November, 2006): NanoBioMagnetics, Inc (NBMI) announced today that Jim Klostergaard, Ph.D., Professor of Molecular and Cellular Oncology at The University of Texas M. D. Anderson Cancer Center, Houston, and Principal Investigator on the NBMI/M. D. Anderson research collaboration, has been invited to present the group's findings at the upcoming annual combined meeting of the European Organization for Research and Treatment of Cancer (EORTC), American Association for Cancer Research (AACR), and the National Cancer Institute (NCI) in Prague, Czech Republic, November 7-10.

Dr. Klostergaard will present a paper titled "Magnetic Localization of Magnetically-Responsive Nanoparticles to Human Ovarian Carcinoma Peritoneal Xenografts." Co-authors on the paper include Dr. Jim Bankson, M. D. Anderson, and Dr. William Yuill and Charles Seeney of NBMI.

This paper follows recent presentations by the research team at the 6th Annual International Conference on Magnetic Carriers in Krems, Austria. The EORTC/AACR/NCI Conference is a unique and internationally recognized forum for the exchange of information on advances in early drug development in the treatment of cancer. This 18th conference is entitled "Molecular Targets and Cancer Therapeutics." The program will cover the entire spectrum of early drug development. Special attention will be given to the preclinical/clinical interphase discussing preclinical and Phase I trials. The conference has been designed to ensure maximum interaction and discussion between scientists, clinicians and those involved in drug development.

Charles Seeney, President and CEO of NBMI, refers to the upcoming presentation as "a significant milestone" on the path to the site-specific delivery of chemotherapeutics.

Based on successful vectoring results in the ovarian model, the NBMI/M. D. Anderson research team will soon follow with localization studies in other tumor models, moving to efficacy studies with drug-loaded nanoparticles. The company is also exploring ways to utilize its platform technology in other areas, such as stem cells and diagnostics.

-30-

For more information:

Mr. Charles Seeney
NanoBioMagnetics, Inc.
Phone: 405.844.5118
Email: seen111@nanobmi.com